All articles by Phillip Broadwith – Page 7
-
Business
Fresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
Business
Job cuts at Amgen, Takeda and Vertex
Takeda reorganising following Ariad takeover, while Amgen and Vertex move staff to Cambridge and San Francisco hubs
-
Business
Analytical data heads to the cloud
Many manufacturers were launching software instead of instruments at Pittcon
-
Business
Expanding precision medicine beyond cancer
Exclusive interview with Koustubh Ranade, vice president of R&D at MedImmune
-
Business
PacBio sues Oxford Nanopore for patent infringement
Firms spar over single-molecule gene sequencing technology
-
Business
J&J to close Scottish medical device plant
Up to 400 positions affected as Ethicon subsidiary leaves Livingston
-
Opinion
Collaboration and competition can both stimulate innovation
Diverse approaches suit different goals
-
Business
Allergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
Business
Daiichi Sankyo to close R&D sites in India and Japan
Closures are part of an ongoing reorganisation aimed at increasing productivity
-
Business
Sabic takes control of Shell petrochemicals joint venture
$820m sale of Saudi Arabian plants continues Shell’s global reorganisation programme
-
Opinion
How much is your chief executive worth?
The executive pay and equality debate is here to stay
-
Business
Lilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
Business
Merck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
Business
Teva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
Business
J&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
Business
Biogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera
-
Business
Former Valeant and Philidor executives arrested for fraud
Prosecutors allege the men masterminded a kickback scheme between Valeant and the speciality pharmacy
-
Business
OCP to invest $3.7bn in Ethiopian fertiliser plant
Output from joint venture between Ethiopian government and Moroccan state phosphate group will exceed domestic demand